Innovations in Migraine Treatment Therapies

According to FutureWise analysis, the Migraine Treatment Market in 2023 was US$2.83 billion, and is expected to reach US$5.64 billion by 2031 at a CAGR of 9.02%. The growing prevalence of migraine disorders and the demand for effective treatments are driving significant growth in the migraine treatment market. Innovations like CGRP monoclonal antibodies and gepants are transforming treatment approaches, while the rise of telehealth services and digital migraine management platforms is enhancing patient access to personalized care and real-time monitoring.

Migraines are complex neurological disorders characterized by recurring episodes of intense throbbing pain, typically on one side of the head. These headaches can persist from four hours to three days and are often accompanied by a variety of other symptoms, including nausea, vomiting, increased sensitivity to sound (phonophobia), increased sensitivity to light (photophobia), tingling or numbness in the extremities, sweating, and diarrhea.

The Migraine Treatment Market is experiencing notable growth, largely driven by a significant increase in the prevalence of migraine cases. Several factors are contributing to this market expansion, including enhanced payment regulations for migraine therapies and a rising demand for precision medications. Additionally, the growing interest in electrical nerve-stimulating devices for migraine treatment and the anticipated approval of innovative late-stage pipeline drugs, such as calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also fueling market progress.

CGRP inhibitors have emerged as a focal point in migraine treatment, with various new formulations and delivery methods currently under research.

A noteworthy development in this field is the study published in June 2025, which explored the effects of liraglutide—a medication primarily used for weight management and diabetes control. The study found that liraglutide significantly reduced the frequency of chronic migraines in individuals with obesity, irrespective of its impact on weight loss. 

FutureWise Market Research has published a report that provides an insightful analysis of Migraine Treatment Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=14662&type=requestsample

Migraine Treatment Market Segmentation:

By Types

• Episodic
• Migraine with Aura
• Chronic
• Others

By Treatment

• Acute/Abortive Treatment
• Preventive/prophylactic Treatment
• Non-Pharmacological Therapies and Devices

By Route of Administration

• Oral
• Parenteral

By Product

• Prescription
• Over The Counter

By Distribution Channel

• Hospital-Based Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By End-Users

• Hospitals
• Clinics
• Homecare
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Migraine Treatment Market:

• Pfizer Inc.
• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Bayer AG
• Allergan
• Abbott
• Allodynic Therapeutics, LLC
• AOBiome
• AstraZeneca
• Aurobindo Pharma USA
• Bausch Health Companies Inc.
• Biohaven Pharmaceuticals
• Catalent, Inc
• Dr. Reddy’s Laboratories Ltd.
• Impel Pharmaceuticals Inc.
• H. Lundbeck A/S
• Merck & Co., Inc
• Boehringer Ingelheim International GmbH

Recent developments by key players in Migraine Treatment Market:

Eli Lilly and Company

• In May 2025, Eli Lilly announced its acquisition of SiteOne Therapeutics for up to $1 billion. This acquisition provides Lilly with access to STC-004, an experimental non-opioid pain treatment that targets Nav1.8 channels, which are involved in pain signal transmission. This strategic move positions Lilly to expand its portfolio in the non-opioid pain relief market, complementing its existing migraine treatments.

Pfizer Inc.

• On March 10, 2023, Pfizer received FDA approval for ZAVZPRET™, the first and only intranasal CGRP receptor antagonist designed for the acute treatment of migraines. In Phase 3 trials, it showed the ability to provide pain relief in as little as 15 minutes and maintain that relief for up to 48 hours.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=14662&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Migraine Treatment Market By Types, By Treatment, By Route of Administration, By Product, By Distribution Channel, By End-Users and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/77194-Innovations-in-Migraine-Treatment-Therapies.html